These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 14728886

  • 1. [Renal protective effect of angiotensin II receptor antagonist on growth hormone-treated nephrotic rats].
    Li S, Cao B, Feng QH, Li XZ.
    Zhonghua Er Ke Za Zhi; 2003 Nov; 41(11):817-21. PubMed ID: 14728886
    [Abstract] [Full Text] [Related]

  • 2. Treatment with irbesatan may improve slit diaphragm alterations in rats with adriamycin-induced nephropathy.
    Wang N, Wei RB, Li P, Li QP, Yang X, Yang Y, Huang MJ, Wang R, Yin Z, Lv Y, Chen XM.
    J Renin Angiotensin Aldosterone Syst; 2016 Nov; 17(2):1470320316646884. PubMed ID: 27169889
    [Abstract] [Full Text] [Related]

  • 3. [Influence of irbesartan on renal hypertrophy and thickening of glomerular basement-membrane in streptozotocin-induced diabetic rats].
    Liu BC, Luo DD, Sun J, Ma KL, Ruan XZ.
    Zhonghua Nei Ke Za Zhi; 2003 May; 42(5):320-3. PubMed ID: 12882713
    [Abstract] [Full Text] [Related]

  • 4. The effects of angiotensin-II receptor blockers on podocyte damage and glomerular apoptosis in a rat model of experimental streptozotocin-induced diabetic nephropathy.
    Tunçdemir M, Oztürk M.
    Acta Histochem; 2011 Dec; 113(8):826-32. PubMed ID: 21269661
    [Abstract] [Full Text] [Related]

  • 5. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ, Lewis JB.
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [Abstract] [Full Text] [Related]

  • 6. Renal protective effects of blocking the intrarenal renin-angiotensin system: angiotensin II type I receptor antagonist compared with angiotensin-converting enzyme inhibitor.
    Zhou A, Yu L, Li J, Zhang J, Wang H.
    Hypertens Res; 2000 Jul; 23(4):391-7. PubMed ID: 10912779
    [Abstract] [Full Text] [Related]

  • 7. Systemic and local effects of angiotensin II blockade in experimental diabetic nephropathy.
    Vieitez P, Gómez O, Uceda ER, Vera ME, Molina-Holgado E.
    J Renin Angiotensin Aldosterone Syst; 2008 Jun; 9(2):96-102. PubMed ID: 18584585
    [Abstract] [Full Text] [Related]

  • 8. Mechanisms of irbesartan in prevention of renal lesion in streptozotocin-induced diabetic rats.
    Liu BC, Chen Q, Luo DD, Sun J, Phillips AO, Ruan XZ, Liu NF.
    Acta Pharmacol Sin; 2003 Jan; 24(1):67-73. PubMed ID: 12511232
    [Abstract] [Full Text] [Related]

  • 9. Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-beta in experimental mesangioproliferative glomerulonephritis.
    Zoja C, Abbate M, Corna D, Capitanio M, Donadelli R, Bruzzi I, Oldroyd S, Benigni A, Remuzzi G.
    Am J Kidney Dis; 1998 Mar; 31(3):453-63. PubMed ID: 9506682
    [Abstract] [Full Text] [Related]

  • 10. Effect of irbesartan on the antioxidant defence system and nitric oxide release in diabetic rat kidney.
    Anjaneyulu M, Chopra K.
    Am J Nephrol; 2004 Mar; 24(5):488-96. PubMed ID: 15353911
    [Abstract] [Full Text] [Related]

  • 11. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis.
    Nakamura T, Obata J, Kimura H, Ohno S, Yoshida Y, Kawachi H, Shimizu F.
    Kidney Int; 1999 Mar; 55(3):877-89. PubMed ID: 10027924
    [Abstract] [Full Text] [Related]

  • 12. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice.
    Liao J, Kobayashi M, Kanamuru Y, Nakamura S, Makita Y, Funabiki K, Horikoshi S, Tomino Y.
    J Nephrol; 2003 Mar; 16(6):841-9. PubMed ID: 14736011
    [Abstract] [Full Text] [Related]

  • 13. The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin.
    Perico N, Remuzzi A, Sangalli F, Azzollini N, Mister M, Ruggenenti P, Remuzzi G.
    J Am Soc Nephrol; 1998 Dec; 9(12):2308-17. PubMed ID: 9848785
    [Abstract] [Full Text] [Related]

  • 14. Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease.
    von Vigier RO, Zberg PM, Teuffel O, Bianchetti MG.
    Eur J Pediatr; 2000 Aug; 159(8):590-3. PubMed ID: 10968237
    [Abstract] [Full Text] [Related]

  • 15. Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats.
    Takai S, Jin D, Sakonjo H, Miyazaki M.
    Hypertens Res; 2010 Sep; 33(9):953-9. PubMed ID: 20520612
    [Abstract] [Full Text] [Related]

  • 16. Renal protection by low dose irbesartan in diabetic nephropathy is paralleled by a reduction of inflammation, not of endoplasmic reticulum stress.
    Hartner A, Cordasic N, Klanke B, Menendez-Castro C, Veelken R, Schmieder RE, Hilgers KF.
    Biochim Biophys Acta; 2014 Apr; 1842(4):558-65. PubMed ID: 24418215
    [Abstract] [Full Text] [Related]

  • 17. CS-886, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats.
    Koga K, Yamagishi S, Takeuchi M, Inagaki Y, Amano S, Okamoto T, Saga T, Makita Z, Yoshizuka M.
    Mol Med; 2002 Oct; 8(10):591-9. PubMed ID: 12477969
    [Abstract] [Full Text] [Related]

  • 18. Amelioration of cyclosporine nephrotoxicity by irbesartan, A selective AT1 receptor antagonist.
    Chander V, Singh D, Tirkey N, Chander H, Chopra K.
    Ren Fail; 2004 Sep; 26(5):467-77. PubMed ID: 15526904
    [Abstract] [Full Text] [Related]

  • 19. [Effects of irbesartan on renal advanced glycation end products and their receptor in rats with early diabetic nephropathy].
    Long HB, Niu HX, Li XY, Zhou WD, He JH, Zhong J, Wei LB.
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 Dec; 29(12):2433-6, 2441. PubMed ID: 20034895
    [Abstract] [Full Text] [Related]

  • 20. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
    Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group.
    N Engl J Med; 2001 Sep 20; 345(12):851-60. PubMed ID: 11565517
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.